A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) in Patients with Advanced Myelofibrosis

Harry Gill* 1, Abdulraheem Yacoub2, Kristen Pettit3, Terrence Bradley4, Aaron Gerds5, Maciej Tatarczuch6, Jake Shortt7, Natasha Curtin7, James Rossetti8, Kate Burbury9, Adam Mead10, Joachim Göthert11, Steffen Koschmieder12, Anna Halpern13, Amber Jones14, Jennifer Peppe14, Georges Natsoulis15, Willis Navarro14, William Stevenson16, Joanne Ewing17 , Ruben Mesa18, Elisa Rumi19, Nicola Vianelli20, Monia Marchetti21, Claire Harrison22, Alessandro Vannucchi23, Justin Watts4, David Ross24, Moshe Talpaz3, Hugh Rienhoff25

INTRODUCTION RESULTS RESULTS LSD1 is a key haematopoietic regulator and overexpressed in MPNs TSS at 12 weeks TSS at 24 weeks

Spleen volume reduction at 24 weeks Haemoglobin and transfusion changes

OBJECTIVE To study the efficacy and safety and efficacy of IMG-7289 in patient with myelofibrosis

Reduction in MAF METHODS

Treatment plan CONCLUSIONS

AFFILIATIONS AND CONTACT 1Department of Medicine, the University of Hong Kong, Hong Kong, China, 2Hematology, University of Kansas, Kansas City, 3Rogel Cancer Center, University of Michigan, Ann Arbor, 4Sylvester Comprehensive Cancer Center, University of Miami, Miami, 5Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States, 6School of Clincal Sciences, Monash University, 7Haematology, Monash Health, Melbourne, Australia, 8Hillman Cancer Center, University of Pittsburgh, Pittsburgh, United States, 9Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia, 10Weatherall Institute of Molecular Medicine , Oxford University, Oxford, United Kingdom, 11West German Cancer Center , University Hospital Essen, Essen, 12Hematology, Aachen University, Aachen, Germany, 13Department of Hematology, University of Washington , Seattle, 14Hematology, 15Genetics, Imago BioSciences, South San Francisco, United States, 16Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia, 17University Hospitals Birmingham, NHS Foundation Trust, Birmingham, United Kingdom, 18UT Health San Antonio Cancer Center, University of Texas Health Science Center, San Antonio, United States, 19Haematology, Fondazione IRCCS Policlinico San Matteo, Pavia, 20Policlinico S.Orsola-Malpighi, Universitaria di Bologna, Bologna, 21Azienda Ospedaliera, SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, 22Department of Clinical Haematology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, 23Center for Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Florence, Italy, 24Haematology, Royal Adelaide Hospital, Adelaide, Australia, 25Hematology, Imago BioSciences, South San Francisco, CA , United States

*Correspondence to Harry Gill, M.D., F.R.C.P, F.R.C.Path., Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.; Tel: (852) 2255 4542; FAX: (852) 2816 2863; Email: gillhsh@ hku.hk